A new drug, gestrinone, was subjected to the first double blind, randomised placebo controlled trial of any treatment of endometriosis. The disease deteriorated in eight (47%) of the 17 patients prescribed placebo (95% confidence limits 23% and 71%) compared with none of the 18 patients prescribed gestrinone (p=0002). There was a difference in elimination of the endometriosis in the gestrinone group compared with placebo but this was not statistically significant (p=0 057). There was a significant difference in improvement of the disease in the gestrinone group compared with placebo (p=0004), confirming that gestrinone is an effective treatment of endometriosis.
If this occurs as long before the onset of preterm labour as does the increase in the saliva oestriol to progesterone ratio before the spontaneous onset of labour at term it might be -possible to use measurements of this ratio to predict preterm labour-and so initiate treatment in time to prevent its occurrence in some cases. Studies are currently underway to address this issue.
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Introduction
Androgens,' progestogens,2 danazol,. and luteinising hormone releasing hormone agonists78 have all been shown to improve endometriosis either clinically or visually in uncontrolled trials.
Before the advent of laparoscopy only symptomatic disease was treated, but now it is becoming increasingly common to diagnose asymptomatic disease, especially in infertile women. The relevance of the finding is unknown and it may be solely a reflection of an increased prevalence of the disease in nulliparous patients, who are overrepresented in infertile women. 9 The problem is compounded by the fact that there is no placebo controlled trial of any treatment of endometriosis and therefore no information about the course of the disease. Possibly asymptomatic endometriosis resolves spontaneously in most women. These uncertainties have resulted in some clinicians treating and others not treating asymptomatic endometriosis. The introduction of gestrinone (Roussel-UCLAF, Paris) for phase III clinical trials provided a unique opportunity to perform-a placebo controlled trial of a treatment of endometriosis and thus define the course of the disease and assess objectively the impact of treatment.
Patients and methods
All the patients were infertile and had been comprehensively investigated with no diagnosis being reached before laparoscopy. Their median age was 28 years (range 21-35) and median duration of infertility 36 months (range 18-72). Each patient was made fully aware of the purpose of the study and of the possibility of allocation to a placebo before giving written consent. The protocol was approved by the local ethical committee.
Study design-The study was a randomised, double blind placebo controlled trial of gestrinone in the treatment of asymptomatic endometriosis. Forty patients were recruited after a laparoscopy at which mild or moderate asymptomatic endometriosis had been diagnosed. The disease was staged using the American Fertility Society scoring system.'0 In this system a score of 1 to 5 signifies mild endometriosis, 6 to 15 moderate endometriosis, and greater than 15 severe disease. Only those patients with asymptomatic disease which did not mechanically impede fertility were included. Patients were allocated at random to either placebo or gestrinone 2-5 mg twice weekly. The treatment lasted 24 weeks, during which the patient was reviewed monthly. In the final week of treatment a repeat laparoscopy was performed. During this procedure the operator (EJT) was unaware of the previous laparoscopic findings and the patient's menstrual history and the observations were verified independently by another gynaecologist.
Statistical methods-We used the technique described by Pocock to determine the number of patients required for the study." Uncontrolled evidence suggested an expected improvement rate of at least 80% in the gestrinone group.'2 The expected improvement rate in the placebo group was unknown, but we considered that the difference from treatment should be at least 50% for gestrinone to have a clinically relevant beneficial effect and therefore set the expected rate at 30%. Type I and type II errors were set at 0 05 and 0-1, respectively. By using these values 16 patients were required in each arm of the trial. In order to allow withdrawals 20 patients were recruited to each arm. Treatment scores before and after treatment were compared using a Wilcoxon rank sum analysis, as the scoring system is non-arithmetic. To simplify the clinical picture outcomes were compared for elimination of, improvement in, and deterioration of the disease. Elimination was defined as no visible disease and improvement as a lower and deterioration as a higher score at the second laparoscopy. The percentages of these observations were compared and the null hypothesis tested by X2 analysis.
Gestrinone is a 19-nortestosterone derivative that has androgenic activity and is an antiprogesterone and antioestrogen. '1 '4 By interacting with hypothalamic and pituitary steroid receptors it decreases the secretion of luteinising hormone and follicle stimulating hormone.'" In some patients this inhibits follicular growth and ovulation, and initially the drug was tested as a contraceptive. 16 It may be that the consequent withdrawal of oestrogen stimulation induces regression of endometriosis, or gestrinone may have this effect directly owing to its antioestrogenic, antiprogestational, and androgenic effects. 12 A dose of either 5 0 or 2-5 mg by mouth twice a week for six months successfully suppresses menstruation, and in three uncontrolled studies it was an effective treatment of endometriosis.12 17 18 The main side effects reported were weight gain, acne, seborrhoea, and hirsutism.
Results
Medians and ranges for age, Quetelet's index (weight (kg)/height squared (m2)), and duration of infertility were similar for both groups. There were five withdrawals. One patient was found to be myxoedematous, one became pregnant within three months of entering the trial, one fractured her right tibia and fibula, and one withdrew during the first month of treatment because she decided against the possibility of being prescribed a placebo.
The last patient withdrew after three months of treatment because she became depressed, which she claimed was unrelated to the medication. This left 18 patients who could be evaluated in the gestrinone group and 17 in the placebo group.
EFFECTS OF GESTRINONE
Gestrinone was well tolerated and no patient withdrew because of side effects. Eight women became amenorrhoeic, in five there were fewer than six episodes of vaginal bleeding, and in five there were six or more episodes. None of the bleeding was cyclical and in all patients it was less than the normal menstrual loss. At four weeks the mean weight increase in the gestrinone group was 2-2 kg (95% confidence limits 1 19 and 3-27). A similar pattern was maintained throughout the treatment period. No significant weight change was observed in the placebo group.-The increase in the gestrinone group was still present eight weeks after treatment.
There was no increase in the incidence of general side effects in the two groups. Table I compares the numbers of patients with seborrhoea or acne on examination in the two groups and shows that they were similar. The Ferriman and Gallwey score was used to assess hirsutism objectively. '9 There was no significant difference in the distribution ofscores either before (z= -0-48; p=0 6) or at the end of treatment (z= -1-05; p=0 3). Table II compares the scores before and after treatment and details the change in scores in the placebo and gestrinone groups. A negative change in score represents improvement, while -a positive change indicates deterioration. The pretreatment score was slightly higher in the placebo than gestrinone group (z= 1-99; p=0 047). The score is a combination of both endometriosis and adhesions, of which gestrinone will affect only the former. When the pretreatment scores were compared for visible disease only there was no difference (z= 1-52; p=O 13). The score for visible endometriosis after treatment was significantly less in the gestrinone group (z=33 11; p=0 002). In order to counterbalance the difference in total scores between the two groups the change in score was compared by Wilcoxon's rank sum analysis. There was a significant difference in favour of the gestrinone group (z= -2-74; p=0 006). Table III compares the outcome in terms of the percentage ofelimination, improvement, and deterioration of endometriosis in the two groups. Using X2 analysis with Yates's correction for continuity we found a highly significant difference in improvement of the disease in the gestrinone group (X2=8*3; 1 df; p=0004) compared with the placebo group. There was a noticeable difference in elimination of the disease but this did not reach commonly accepted levels of statistical significance (X2=3-64; 1 df; p=0057). The frequency of deterioration ofthediseasein the placebo group was significantly higher than that in the gestrinone group (p=0002, two sided Fisher's exact test).
The placebo group was divided into those patients in whom the disease deteriorated (n=8) and those in whom it did not (n=9) and the medians and ranges for age, parity, Quetelet's index, and duration ofinfertility compared. There was no significant difference in the range of any of these factors between the two subgroups. Discussion This is the first randomised placebo controlled trial of any treatment of endometriosis. Observation of the course of asymptomatic mild and moderate disease over six months has shown that it deteriorates in a large number of patients (95% confidence limits 23% and 7 1%), which does not occur in those having treatment. We think that this level ofdeterioration in untreated disease means that finding endometriosis at laparoscopy, even if asymptomatic, warrants starting treatment. Gestrinone is an effective treatment of endometriosis.
The recommendation to treat asymptomatic disease is further supported by our finding that in three patients in the placebo group the degree ofdeterioration included the appearance ofadhesions that resulted in ovarian enclosure. These adhesions may mechanically impede future fertility and their appearance is of considerable importance in infertile women, who are commonly diagnosed with asymptomatic disease. The finding that no factor, including the original score, could accurately predict improvement or deterioration in the placebo group also supports the recommendation that asymptomatic disease should always be treated.
The study has shown a beneficial impact of gestrinone on the course of asymptomatic endometriosis. The laparoscopy was performed in the final week of treatment, which raises two criticisms of the study. Firstly, there may have been quiescent areas of endometriosis which would have become visible if stimulated by oestradiol. There is conflicting evidence about the relation between endometriosis and ovarian-steroids and recent studies have reported that the disease can be neither morphologically2'21 nor functionally22 considered simply as ectopic endometrium. It is therefore doubtful whether the size or symptomatology of the disease would have been altered by a short period of ovarian steroid stimulation. The second criticism is that the study does not show a permanent effect of the drug. The trial did not address this question, but as the drug is unlikely to alter whatever predisposes a person to endometriosis possibly the disease will recur. In order to answer the question it would be necessary to perform a further laparoscopy some months after completing treatment.
The drug was well tolerated and the absence of androgenic side effects contradicts previous uncontrolled studies. '2 1718 The presence of the placebo control balanced any apparent increase in any side effect in the gestrinone group. The number of patients means that the study cannot rule out a small increase in the incidence of androgenic side effects but it discounts a severe effect. As the gain in weight with gestrinone did not disappear after treatment probably it represents an increase in muscle and adipose tissue and not simply fluid retention. This is probably a result of the androgenicity of the drug and is the most tangible side effect.
In summary this study has shown a beneficial impact of treatment on the course of asymptomatic endometriosis. The usual course is for the disease to deteriorate in a proportion ofwomen, and as this is unpredictable we recommend that all patients should be treated.
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YEARS AGO
A good deal of dissatisfaction has been expressed in many quarters at the substitution of the word "margarine" for that of "butterine" in the Bill now before Parliament. Sir Lyon Playfair, in a letter to the Times, in which he advocates the use of the word "butter-substitute," points out that "'margarine' is scientific nonsense and a practical absurdity. Stearine and margarine are solid fats used to give solidity to candles, and do not resemble soft butter in any degree. If the scientific name had been desired, it should have been 'oleo-margarine,' which is a soft fat resembling butter;" and he asks: "Why should the working-classes be perplexed with a scientific name? Butterine," he adds, "is a wholesome butter-substitute made from the fat of the ox, as butter is made from the fat of the cow. It contains about 95 per cent. of the same fatty materials as those in ordinary butter, and differs only by not containing the aromatic fatty acids which give to good butter its delicious flavour. But if the poor choose to buy ox-butter at 6d. per lb., why should they have difficulties in procuring it in favour of cow-butter at is. per lb." For the efficient working of a measure of this kind it is a matter of the first importance that there should be a correct use of terms, and such as are readily understood by the class ofpersons who are affected by its provisions.
Butterine, however, is, it may be argued, itself misleading, as implying a variety of food made from milk; this butterine is certainly not. If margarine or ole;o-margarine be objected to, then some new specific or fancy designation might be devised; but we can well understand the existing objections to the name of "butter" to one which it is contended is more or less sailing under false pretences. (BritishMedicaljournal 1887;ii:97.)
